Jen Marvin-Peek, MD
@JenMarvinPeek
Followers
108
Following
127
Media
0
Statuses
56
Current Heme/Onc Fellow @MDAndersonNews and Dog Lover 🐾|| Alumni of @VUMCMedicineRes and @VUMedicine || Interested in #leukemia ||Tweets are my own
Houston, TX
Joined October 2023
➡️ Happy to share our analysis on the adverse prognostic impact of ASXL1-mut AML 🩸 among ELN2024 Fav, LIT+Ven treated patients at ##ASH2025 from @MDAndersonNews. Great work by @JenMarvinPeek, and part of ongoing analysis.
0
10
40
👉👉👉We are super proud to welcome our newest class of Heme/Onc Fellow MDs to @MDAndersonNews !!! 📣 Congratulations! @KellyMezaMD @HannahGoulart @JenMarvinPeek @lungoncdoc @VanMorrisMD @homesforhealers @marklewismd @Daver_Leukemia @mtmdphd | #MatchDay #Fellowship #meded
4
11
93
A privilege to be part of this important guideline recommendation about how to optimize frontline triplet regimens in AML w/ a stellar group of colleagues 👇@Daver_Leukemia @jaltmanmd @CLachowiez @JenMarvinPeek @UNC_Lineberger
Excellent Current Treatment Algorithm article. Open access! Optimizing lower intensity triplet therapy in acute myeloid leukemia.
2
4
23
👉👉👉Happy Thanksgiving ! Leukemia team quick meet-up for lunch ! Lovely colleagues & friends! #leusm #MPNSM | @doctorpemm @NitinJainMD @JenMarvinPeek @jenweiying #AlexBazinet @ChenLilyY | @HemeReports @MpncoD
1
4
45
New publication 📝 A pooled analysis, published in @JCO_ASCO, shows HMA + venetoclax + IDH inhibitor triplet regimen was well tolerated and improved outcomes in IC-ineligible patients with newly diagnosed IDH-mutated AML. Learn more: https://t.co/RLmHJTyV9W
#AMLsm #leusm
0
1
2
👉👉👉Major new paper 📑 👉just out in BJH led by Dr .@jenweiying & Dr .@TapKadia @MDAndersonNews 📣 #MECOM fusion partner & bone marrow blast % influence outcomes of patients w/#MECOM -rearranged AML | @sanamloghavi
https://t.co/Gx8flN1LR2
#endcancer #leusm #MECOM
1
14
43
👉👉👉Wonderful to meet up with the future leaders of leukemia research ! @doctorpemm w/ Dr Alex Bazinet , Dr @jenweiying & Dr @JenMarvinPeek | #leusm #MPNSM #BPDCN | #endcancer
0
4
21
👉Here is an updated version of the Table which I initially posted post ASH2024. 👉Now Updated with EHA 2025 data including updated FLAIR, CLL13, CAPTIVATE trials. #CLL
5
42
122
Acute myeloid leukemia remains one of the most heterogeneous hematologic malignancies, and accurate risk stratification continues to be a moving target. https://t.co/PSeLUJIYvp
#myeloidneoplasia
ashpublications.org
In this issue of Blood, Reville et al have identified oncostatin M receptor (OSMR) as a serum-based biomarker predicting acute myeloid leukemia (AML) outco
2
3
23
Our #Opal bone marrow image is featured on the new @BloodPortfolio cover, highlighting the discovery of OSMR as a novel #AML biomarker. This work was led by @HusseinAbbasLab, @patrickreville, @BofeiWang3 and @JenMarvinPeek at @MDAndersonNews. Learn more: https://t.co/VzHz9edftU
0
3
8
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML. Co-authored by @JenMarvinPeek. Full article.
ascopubs.org
PURPOSEThe development of targeted therapeutics has revolutionized treatment for elderly patients with AML. Two doublet regimens are approved in the frontline setting for intensive chemotherapy...
3
11
35
👉 Check the Top #AML #abstracts at #EHA2025 by date and ID Many presented by our #Leukemia Faculty & Fellows from @MDAndersonNews Looking forward to exciting discussions & new treatment options for patients at @EHA_Hematology @OncoAlert @AML_Hub #leusm
5
17
60
So thankful to @ConquerCancerFd for the 2025 @ASCO YIA! I am especially grateful to my amazing mentors and to @MDAndersonNews for their unwavering support and guidance. Congrats to my fellow awardees. Proud to be a part of this inspiring group! #makingcancerhistory
Congratulations to this year’s class of Conquer Cancer grant and award recipients! Are you one of them? Tell us in the comments! We can't wait to celebrate with you at #ASCO25. Full list of recipients: https://t.co/aE89Mrvgeu
@ASCO
8
10
65
Online Now! Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia https://t.co/NXOv7GkyJK
#stemcells
1
8
34
MD Anderson (@MDAndersonNews) Research Highlights @BoyiGan @StevenLin_MDPhD @HusseinAbbasLab @iveletic @Daver_Leukemia @jayastuMD @DrKrinaPatel @RNGisele
https://t.co/6KPex79IRd
#OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #CART #AML #CLL
0
3
21
➡️ Rates of HSCT and Upset bar plot showing barriers to HSCT in frontline TP53-mut AML
0
6
17
Amazing! Congratulations to my friend and co-fellow @NazliDizman 🎉
So proud of to call @NazliDizman & @FernandoDiazMD1 not only colleagues, but good friends thanks to @ASCO 📸 today of 2 former @ASCOTECAG Chairs celebrating the upcoming 2025-2026 Trainee & Early Career Advisory Group Chair Dr. Nazli Dizman!!! Missing @ramsedhom & Jacob!
0
2
8
New publication, online now @BloodJournal Blood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML Outcomes @BofeiWang3 @JenMarvinPeek @HusseinAbbasLab
https://t.co/KECo8UzGsP
ashpublications.org
Key PointsLIRS, comprising 8 proteins, is highly predictive of patient outcomes and refine the risk stratification in AML.Oncostatin M receptor is a single
4
8
37
🙂 Very Happy to share this comprehensive review on AML, from an @MDAndersonNews perspective, discussing all that is new and exciting in the field 🩸 @DrHKantarjian ➡️ Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges @AcsCancer
12
60
232
Updated results of our frontline trial of FLAG-IDA+VEN, showing CRc in 95% of newly diagnosed #AML. Responses were seen across all ELN22 risk groups, w/ 90% MRD neg. In RR AML, 79% first salvage & TP53wt attained CRc. @MDAndersonNews
https://t.co/I7S7afDUbf
@LeukemiaJnl
8
45
171